Mass spectrometry-based proteomic analysis to characterize cisplatin induced early signaling events in head and neck squamous cell carcinoma

References

• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–9. doi:10.1016/j.ejphar.2014.07.025.
   PubMed Web of Science ®Google Scholar
• Pietras P, Aulas A, Fay MM, Leśniczak-Staszak M, Sowiński M, Lyons SM, Szaflarski W, Ivanov P. Translation inhibition and suppression of stress granules formation by cisplatin. Biomed Pharmacother. 2022;145:112382. doi:10.1016/j.biopha.2021.112382.
   PubMed Web of Science ®Google Scholar
• Bostan M, Petrică‑Matei GG, Ion G, Radu N, Mihăilă M, Hainăroşie R, Braşoveanu L, Roman V, Constantin C, Neagu M. et al. Cisplatin effect on head and neck squamous cell carcinoma cells is modulated by ERK1/2 protein kinases. Exp Ther Med. 2019;18(6):5041–5051. doi:10.3892/etm.2019.8139.
   PubMed Web of Science ®Google Scholar
• Ebhardt HA, Root A, Liu Y, Gauthier NP, Sander C, Aebersold R. Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer. NPJ Syst Biol Appl. 2018;4(1):26. doi:10.1038/s41540-018-0064-1.
   PubMedGoogle Scholar
• Musiani D, Hammond DE, Cirillo L, Erriquez J, Olivero M, Clague MJ, Di Renzo MF. PIM2 kinase is induced by cisplatin in ovarian cancer cells and limits drug efficacy. J Proteome Res. 2014;13(11):4970–4982. doi:10.1021/pr500651n.
   PubMed Web of Science ®Google Scholar
• Mitchell DC, Kuljanin M, Li J, Van Vranken JG, Bulloch N, Schweppe DK, Huttlin EL, Gygi SP. A proteome-wide atlas of drug mechanism of action. Nat Biotechnol. 2023;41(6):845–857. doi:10.1038/s41587-022-01539-0.
   PubMed Web of Science ®Google Scholar
• Frejno M, Meng C, Ruprecht B, Oellerich T, Scheich S, Kleigrewe K, Drecoll E, Samaras P, Hogrebe A, Helm D. et al. Proteome activity landscapes of tumor cell lines determine drug responses. Nat Commun. 2020;11(1):3639. doi:10.1038/s41467-020-17336-9.
   PubMed Web of Science ®Google Scholar
• Frejno M, Zenezini Chiozzi R, Wilhelm M, Koch H, Zheng R, Klaeger S, Ruprecht B, Meng C, Kramer K, Jarzab A. et al. Pharmacoproteomic characterisation of human colon and rectal cancer. Mol Syst Biol. 2017;13(11):951. doi:10.15252/msb.20177701.
   PubMed Web of Science ®Google Scholar
• Borse V, Konwar AN, Buragohain P. Oral cancer diagnosis and perspectives in India. Sens Int. 2020;1:100046. doi:10.1016/j.sintl.2020.100046.
   Google Scholar
• Griso AB, Acero-Riaguas L, Castelo B, Cebrian-Carretero JL, Sastre-Perona A. Mechanisms of cisplatin resistance in HPV negative head and neck squamous cell carcinomas. Cells. 2022;11(3):561. doi:10.3390/cells11030561.
   PubMed Web of Science ®Google Scholar
• Nanjappa V, Renuse S, Sathe GJ, Raja R, Syed N, Radhakrishnan A, Subbannayya T, Patil A, Marimuthu A, Sahasrabuddhe NA. et al. Chronic exposure to chewing tobacco selects for overexpression of stearoyl-CoA desaturase in normal oral keratinocytes. Cancer Biol Ther. 2015;16(11):1593–1603. doi:10.1080/15384047.2015.1078022.
   PubMed Web of Science ®Google Scholar
• Perez-Riverol Y, Bai J, Bandla C, García-Seisdedos D, Hewapathirana S, Kamatchinathan S, Kundu D, Prakash A, Frericks-Zipper A, Eisenacher M. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 2022;50(D1):D543–D552. doi:10.1093/nar/gkab1038.
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman W-H, Pagès F, Trajanoski Z, Galon J. et al. ClueGO: a cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25(8):1091–1093. doi:10.1093/bioinformatics/btp101.
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:10.1101/gr.1239303.
   PubMed Web of Science ®Google Scholar
• Kutmon M, van Iersel MP, Bohler A, Kelder T, Nunes N, Pico AR, Evelo CT. PathVisio 3: an extendable pathway analysis toolbox. PLoS Comput Biol. 2015;11(2):e1004085. doi:10.1371/journal.pcbi.1004085.
   PubMed Web of Science ®Google Scholar
• Liu YQ, Zhang GA, Zhang BC, Wang Y, Liu Z, Jiao Y-L, Liu N, Zhao Y-R. Short low concentration cisplatin treatment leads to an epithelial mesenchymal transition-like response in DU145 prostate cancer cells. Asian Pac J Cancer Prev. 2015;16(3):1025–1028. doi:10.7314/APJCP.2015.16.3.1025.
   PubMedGoogle Scholar
• Zou J, Zhu L, Jiang X, Wang Y, Wang X, Chen B. Curcumin increases breast cancer cell sensitivity to cisplatin by decreasing FEN1 expression. Oncotarget. 2018;9(13):11268–11278. doi:10.18632/oncotarget.24109.
   PubMedGoogle Scholar
• Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and mutagenesis. Environ Mol Mutagen. 2017;58(5):235–263. doi:10.1002/em.22087.
   PubMed Web of Science ®Google Scholar
• Huang H, Han Y, Zhang C, Wu J, Feng J, Qu L, Shou C. HNRNPC as a candidate biomarker for chemoresistance in gastric cancer. Tumour Biol. 2016;37(3):3527–3534. doi:10.1007/s13277-015-4144-1.
   PubMedGoogle Scholar
• Taoka Y, Matsumoto K, Ohashi K, Minamida S, Hagiwara M, Nagi S, Saito T, Kodera Y, Iwamura M. Protein expression profile related to cisplatin resistance in bladder cancer cell lines detected by two-dimensional gel electrophoresis. Biomed Res. 2015;36(4):253–261. doi:10.2220/biomedres.36.253.
   PubMed Web of Science ®Google Scholar
• Gabriel M, Delforge Y, Deward A, Habraken Y, Hennuy B, Piette J, Klinck R, Chabot B, Colige A, Lambert C. et al. Role of the splicing factor SRSF4 in cisplatin-induced modifications of pre-mRNA splicing and apoptosis. BMC Cancer. 2015;15(1):227. doi:10.1186/s12885-015-1259-0.
   PubMedGoogle Scholar
• Huang D, Savage SR, Calinawan AP, Lin C, Zhang B, Wang P, Starr TK, Birrer MJ, Paulovich AG. A highly annotated database of genes associated with platinum resistance in cancer. Oncogene. 2021;40(46):6395–6405. doi:10.1038/s41388-021-02055-2.
   PubMed Web of Science ®Google Scholar
• Kato A, Naitoh I, Naiki-Ito A, Hayashi K, Okumura F, Fujita Y, Sano H, Nishi Y, Miyabe K, Inoue T. et al. Class III β-tubulin expression is of value in selecting nab-paclitaxel and Gemcitabine as first-line therapy in unresectable pancreatic cancer. Pancreas. 2022;51(4):372–379. doi:10.1097/MPA.0000000000002032.
   PubMed Web of Science ®Google Scholar
• Maahs L, Sanchez BE, Gupta N, Van Harn M, Barrack ER, Reddy P-V, Hwang C. Class III β-tubulin expression as a predictor of docetaxel-resistance in metastatic castration-resistant prostate cancer. PLoS One. 2019;14(10):e0222510. doi:10.1371/journal.pone.0222510.
   PubMed Web of Science ®Google Scholar
• Miyata Y, Matsuo T, Nakamura Y, Yasuda T, Ohba K, Takehara K, Sakai H. Expression of class III beta-tubulin predicts prognosis in patients with cisplatin-resistant bladder cancer receiving paclitaxel-based second-line chemotherapy. Anticancer Res. 2018;38(3):1629–1635.
   PubMed Web of Science ®Google Scholar
• Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, Beqiri M, Sproesser K, Brafford PA, Xiao M. et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature. 2017;546(7658):431–435. doi:10.1038/nature22794.
   PubMed Web of Science ®Google Scholar
• Valiron O, Caudron N, Job D. Microtubule dynamics. Cell Mol Life Sci. 2001;58(14):2069–2084. doi:10.1007/PL00000837.
   PubMed Web of Science ®Google Scholar
• Person F, Wilczak W, Hube-Magg C, Burdelski C, Möller-Koop C, Simon R, Noriega M, Sauter G, Steurer S, Burdak-Rothkamm S. et al. Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers. Tumour Biol. 2017;39(10):1010428317712166. doi:10.1177/1010428317712166.
   Google Scholar
• Choi JW, Kim Y, Lee JH, Kim YS. Expression of beta-tubulin isotypes in urothelial carcinoma of the bladder. World J Urol. 2014;32(2):347–352. doi:10.1007/s00345-012-0993-z.
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, Mozzetti S, Scambia G, Ferlini C. Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res. 2006;12(9):2774–2779. doi:10.1158/1078-0432.CCR-05-2715.
   PubMed Web of Science ®Google Scholar
• Koh Y, Jang B, Han SW, Kim T-M, Oh D-Y, Lee S-H, Kang CH, Kim D-W, Im S-A, Chung DH. et al. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol. 2010;5(3):320–325. doi:10.1097/JTO.0b013e3181ce684f.
   PubMed Web of Science ®Google Scholar
• Koh Y, Kim TM, Jeon YK, Kwon T-K, Hah JH, Lee S-H, Kim D-W, Wu H-G, Rhee C-S, Sung M-W. et al. Class III β-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2009;20(8):1414–1419. doi:10.1093/annonc/mdp002.
   PubMed Web of Science ®Google Scholar
• Di Bartolomeo M, Raimondi A, Cecchi F, Catenacci DVT, Schwartz S, Sellappan S, Tian Y, Miceli R, Pellegrinelli A, Giommoni E. et al. Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. Tumori. 2021;107(2):150–159. doi:10.1177/0300891620930803.
   PubMed Web of Science ®Google Scholar
• Na HY, Park M, Kim YA, Won JK, Park YJ, Shin SA, Lee S, Oh S, Kim JE. Expression of class III beta-tubulin is associated with invasive potential and poor prognosis in thyroid carcinoma. J Clin Med. 2020;9(12):3830. doi:10.3390/jcm9123830.
   PubMed Web of Science ®Google Scholar
• Sekino Y, Han X, Babasaki T, Miyamoto S, Kitano H, Kobayashi G, Goto K, Inoue S, Hayashi T, Teishima J. et al. TUBB3 is associated with high-grade histology, poor prognosis, p53 expression, and cancer stem cell markers in clear cell renal cell carcinoma. Oncology. 2020;98(10):689–698. doi:10.1159/000506775.
   PubMed Web of Science ®Google Scholar
• Kamath K, Wilson L, Cabral F, Jordan MA. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem. 2005;280(13):12902–12907. doi:10.1074/jbc.M414477200.
   PubMed Web of Science ®Google Scholar
• Stengel C, Newman SP, Leese MP, Potter BV, Reed MJ, Purohit A. Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer. 2010;102(2):316–324. doi:10.1038/sj.bjc.6605489.
   PubMed Web of Science ®Google Scholar
• Gan PP, Pasquier E, Kavallaris M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res. 2007;67(19):9356–9363. doi:10.1158/0008-5472.CAN-07-0509.
   PubMed Web of Science ®Google Scholar